ICE-R regimen
|
WikiDoc Resources for ICE-R regimen |
|
Articles |
|---|
|
Most recent articles on ICE-R regimen Most cited articles on ICE-R regimen |
|
Media |
|
Powerpoint slides on ICE-R regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on ICE-R regimen at Clinical Trials.gov Trial results on ICE-R regimen Clinical Trials on ICE-R regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on ICE-R regimen NICE Guidance on ICE-R regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on ICE-R regimen Discussion groups on ICE-R regimen Patient Handouts on ICE-R regimen Directions to Hospitals Treating ICE-R regimen Risk calculators and risk factors for ICE-R regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for ICE-R regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:R-ICE Regimen; RICE Regimen; Rituximab-Ifosfamide-Carboplatin-Etoposide Regimen
Overview
ICE-R regimen refers to a chemoimmunotherapy regimen consisting of rituximab, ifosfamide, carboplatin and etoposide used to treat indolent and aggressive forms of non-Hodgkin's lymphoma; also used to treat relapsed and refractory non-Hodgkin's lymphoma.[1][2]
Regimen
RRituximab
IIfosfamide
CCarboplatin
EEtoposide
Indications
- Relapsed and refractory non-Hodgkin's lymphoma.[1]
References
- ↑ 1.0 1.1 Vose J, Sneller V (2003). "Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma". Ann Oncol. 14 Suppl 1: i17–20. PMID 12736226.
- ↑ "NCI Thesaurus".